08/17/2011Researchers in the United Kingdom have discovered a new genetic mutation that increases the risk for ovarian cancer. This major finding was published online in the journal Nature Genetics on … Continued
08/09/2011 Earlier this year, OCRF welcomed two new members to its Scientific Advisory Committee: Ronny I. Drapkin, MD, PhD and Sandra Orsulic, PhD. Both Drs. Drapkin and Orsulic are experts … Continued
Drop by the Petaluma Arts Center on September 2, and you will find a building bedecked in teal. The Women’s Cancer Awareness Group is using “yarn-bombing”—decorating a public structure or … Continued
The Ovarian Cancer National Alliance’s 14th Annual Conference, “Turning Promise into Action,” just wrapped up. What a conference it was! Hundreds of researchers, clinicians, survivors and caregivers attended the largest … Continued
When Jean Shipos survived a recurrence of ovarian cancer in 2003, she and her daughter vowed to raise awareness of the disease. They got involved with a local run/walk, organizing … Continued
In a paper published on June 30, 2011 in the journal Nature, researchers working as part of The Cancer Genome Atlas (TCGA) Research Network report that they have created a … Continued
Kelly Smith founded the Ovarian Cancer Alliance of North Florida while she was on spring break from college one year. Based in Tallahassee, this Partner Member focuses on younger women, … Continued
Ovarian cancer patients had a twofold greater risk of gastrointestinal adverse effects when bevacizumab was added to chemotherapy, but the angiogenesis inhibitor did not exacerbate other known risks for GI events, data from a large prospective trial showed.
Ovarian cancer patients had a twofold greater risk of gastrointestinal adverse effects when bevacizumab was added to chemotherapy, but the angiogenesis inhibitor did not exacerbate other known risks for GI events, data from a large prospective trial showed.
Most survivors of gynecologic cancers have menopausal symptoms, and at least one in four takes replacement hormones, results of the first study of its kind showed.
Developers of a genetic-susceptibility test for ovarian cancer might have jumped the gun, according to an OCRF-funded research consortium that found no association between a KRAS mutation and risk of the cancer.
Cancer recurrence and death occurred significantly more often in ovarian cancer patients treated with erythropoietin-stimulating agents (ESAs), data from a retrospective cohort review showed.
Get email updates about research news, action alerts, and ways to join the fight.
